2 Oversold Stocks With Major Reasons to Rebound
The recent market selloff has left very few areas untouched. Fear and panic are taking hold as trade wars, tariffs, and economic uncertainty ripple through the financial landscape. But it's not all doom and gloom. While the broader market pulls back, this downturn might present some compelling opportunities, especially for stocks trading near key support levels or at what could be considered a discount.
That seems to be the case with the two stocks below. Both have sold off sharply from their recent highs, yet they've also posted solid earnings beats. This intriguing combination of positive fundamentals and technical pullbacks suggests that these two names might be primed for a rebound.
MercadoLibre: A Blowout Quarter, Now 11% Off Highs
[content-module:Forecast|NASDAQ:MELI]
MercadoLibre, Inc. (NASDAQ: MELI) is Latin America's largest e-commerce and fintech platform. It operates in 18 countries, connecting millions of buyers and sellers through its online marketplace and offering various digital payments, logistics, and financial services.
Despite delivering knockout Q4 2024 earnings, MELI has tumbled more than 11% from its recent 52-week highs. The pullback seems tied to broader U.S. stock market weakness and a dose of profit-taking rather than any fundamental issues with the company itself. For long-term investors, this retreat could be a welcome buying opportunity.
MercadoLibre's Q4 numbers were nothing short of impressive. Revenue soared to $6.1 billion, a 37% year-over-year jump that easily beat Wall Street's $5.9 billion estimate. Net income surged to $639 million, smashing the $402 million forecast. The marketplace remains on fire, with gross merchandise volume hitting $14.5 billion, up 56% when adjusted for currency swings. Meanwhile, its fintech arm, Mercado Pago, processed $58.9 billion in payments, up 33%, and its credit portfolio expanded by 74%, reaching $6.6 billion.
With the stock returning to a key support zone, previous resistance is now turned to support. This could be a golden entry point for investors seeking exposure to one of Latin America's most dominant tech companies. The fundamentals are strong, and this dip may not last long.
PayPal: Solid Earnings, Oversold Stock
[content-module:Forecast|NASDAQ:PYPL]
PayPal Holdings (NASDAQ: PYPL) needs no introduction as one of the world's largest and most established fintech companies, dating back to 1998. However, despite its long-standing leadership in digital payments, its stock has recently fallen out of favor.
After an aggressive selloff post-earnings, PayPal is now in correction territory, down nearly 19% year-to-date. The Q4 2024 report, released on February 4, 2025, showed solid results that topped expectations. Revenue rose 4% year-over-year to $8.37 billion, edging past analyst estimates of $8.3 billion. Net income reached $1.2 billion, with adjusted earnings per share (EPS) of $1.19, beating the $1.14 consensus forecast. Total payment volume (TPV) climbed 7% to $437.8 billion, just shy of the $438.2 billion projection.
Adding to its long-term appeal, PayPal announced a $15 billion share buyback program, with $6 billion planned for 2025. This shows strong confidence in its growing cash flow, which surged 40% to $2.1 billion for the quarter.
Yet, despite these positives, the stock dropped nearly 10% post-earnings, mainly due to concerns about slowing branded checkout growth and slightly lower transaction take rates. Still, PayPal guided for 2025 EPS of $4.95 to $5.10, exceeding Wall Street's $4.90 estimate, signaling a clear focus on growth and operational efficiency.
Now trading below its 200-day moving average, with an oversold RSI and hovering near a support zone around $65, PayPal might be an attractive buy-the-dip candidate. For investors willing to look past the short-term noise, this could be a prime moment to grab shares of a fintech leader with a strong turnaround narrative.
The Bottom Line
While fear has gripped the markets, not all sell-offs are permanent. MercadoLibre and PayPal have delivered strong earnings yet are trading at potential discounts. These two oversold stocks may be worth a closer look for investors seeking quality names with solid fundamentals and promising technical setups.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Why AppFolio Stock Rocked the Market on Tuesday
One quite active stock mover on a forgettable Tuesday for the market was specialized business software developer AppFolio (NASDAQ: APPF). The company's shares saw a robust rise of almost 5% across the trading day, thanks to a pair of insider stock buys disclosed in regulatory filings. On that day, the S&P 500 (SNPINDEX: ^GSPC) also rose but by nowhere near as much, inching up to close the day 0.6% higher. A pair of very familiar stock buyers The two AppFolio folks snapping up shares of the company were members of its board of directors, Timothy Bliss and Casey Donald. Of the pair, Bliss was the more assertive, as he amassed 22,000 shares in a series of buys between last Thursday and the following Monday. The per-share price he paid for each of these blocks ranged from $215.28 to $218.73. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As for Donald, his buying activity was more muted and concentrated. In a single purchase made last Friday, he snapped up 4,000 shares, paying an average of $217.73 apiece for the privilege. Shares of AppFolio, a software-as-a-service (SaaS) company that focuses on the real estate market, have seen something of an upswing lately. In no small part, this is a recovery from a sell-off following the company's first-quarter earnings release, published in late April. Although it posted solid growth on the top line, its net income fell, and it missed analyst estimates for both metrics. Lofty expectations We should bear in mind that investor expectations for the often-prosperous SaaS segment can be awfully high. Often, folks invested in industry titles demand not only strong, across-the-board growth; they insist on crushing beats too. To me, AppFolio is still doing very well in its niche, and remains robustly profitable despite that recent bottom-line dip. I think those insider buys were smart. Should you invest $1,000 in AppFolio right now? Before you buy stock in AppFolio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AppFolio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
5 hours ago
- Globe and Mail
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit ('RSU') awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the '2021 Inducement Plan'). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $33.08 per share, which is equal to the closing price of Crinetics' common stock on the Nasdaq Global Select Market on June 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee's continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@ (858) 345-6340
Cision Canada
6 hours ago
- Cision Canada
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th
TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time. A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the outcomes of the clinical trial and future submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected]
